OmniAb to Participate in Two Investor Conferences in November

$OABI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Get the next $OABI alert in real time by email

OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating in two investor conferences during the month of November.

  • Stifel 2024 Healthcare Conference, November 18-19 at the Lotte New York Palace Hotel. Kurt Gustafson, Chief Financial Officer, will participate in one-on-one meetings with investors on Tuesday, November 19th.
  • Jefferies London Healthcare Conference, November 19-21 at the Waldorf Hilton. Matt Foehr, Chief Executive Officer, will participate in one-on-one and small-group meetings with investors on November 19-20.

About OmniAb®

OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners' drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™ (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics.

Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAb™, is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb's technology and creates opportunities in many important and emerging target classes.

OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others.

For more information, please visit www.omniab.com.

Get the next $OABI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New
  • What investor conferences will OmniAb participate in during November?

    OmniAb's management will participate in two upcoming investor conferences: the Stifel 2024 Healthcare Conference and the Jefferies London Healthcare Conference.

  • Who from OmniAb is speaking at each conference and when?

    Kurt Gustafson, Chief Financial Officer, will meet with investors on November 19 at the Stifel Healthcare Conference, and Matt Foehr, CEO, will meet on November 19-20 at the Jefferies London Healthcare Conference.

  • What is the core technology of OmniAb and its purpose?

    OmniAb's technology focuses on discovering next-generation therapeutics using advanced research technologies and engineered transgenic animals for antibody generation.

  • What are some examples of OmniAb's proprietary transgenic animals and their functions?

    The proprietary transgenic animals include OmniRat®, OmniChicken®, and OmniMouse®, which are genetically modified to generate fully-human antibodies for drug development.

  • What types of therapeutic modalities can OmniAb's technologies be used for?

    OmniAb's technologies are applicable for various antibody-based therapeutics, such as bi-specific biologics, CAR-T therapies, and antibody-drug conjugates.

Recent Analyst Ratings for
$OABI

DatePrice TargetRatingAnalyst
11/29/2023$6.00Outperform
RBC Capital Mkts
4/21/2023$8.00Buy
The Benchmark Company
4/13/2023$10.00Buy
Craig Hallum
2/22/2023$10.00Outperform
Cowen
2/13/2023$11.00Buy
H.C. Wainwright
More analyst ratings

$OABI
Press Releases

Fastest customizable press release news feed in the world

See more
  • OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

    Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. "2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach," said Matt Foehr, Chief Executive Officer of OmniAb. "We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our co

    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • OmniAb to Report Fourth Quarter 2024 Financial Results on March 18

    OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tuesday, March 18, 2025 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss fourth quarter financial results and business updates       Date:   Tuesday, March 18, 2025       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549 8228     International (289) 819 1520     Conference ID is 84579

    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • OmniAb to Participate in Two Investor Conferences in March

    OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating in two investor conferences during the month of March. TD Cowen 45th Annual Health Care Conference, March 3-5 at the Boston Marriott Copley Place. Management will be presenting a corporate overview on Tuesday, March 4th at 2:30 p.m. Eastern time and will be holding one-on-one meetings with investors. 2025 Leerink Partners Global Healthcare Conference, March 9-12 at the W Hotel South Beach in Miami. Management will hold one-on-one meetings with investors on Wednesday, March 12th. About OmniAb® OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic

    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$OABI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$OABI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$OABI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$OABI
SEC Filings

See more

$OABI
Leadership Updates

Live Leadership Updates

See more
  • OmniAb Appoints Steve Love to its Board of Directors

    OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$OABI
Financials

Live finance-specific insights

See more
  • OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

    Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. "2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach," said Matt Foehr, Chief Executive Officer of OmniAb. "We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our co

    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • OmniAb to Report Fourth Quarter 2024 Financial Results on March 18

    OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tuesday, March 18, 2025 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss fourth quarter financial results and business updates       Date:   Tuesday, March 18, 2025       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549 8228     International (289) 819 1520     Conference ID is 84579

    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

    Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. "We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Third quarter results reflect consistent growth across key metrics, driven by our planned initiatives and the dedication of our team," said Matt Foehr, Chief Executive Officer of OmniAb. "Our business is well capitalized, and we have a highly scalable model with cutting-

    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$OABI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more